Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Zepbound

Lilly Says Weight Loss Drug Prices Fell 13 Percent Worldwide, but the US Decline Was Far Smaller

Lilly reported a 13% drop in realized prices, but US prices fell only 3%. Here is what that means for Zepbound patients and out-of-pocket costs.

Medical Daily

Eli Lilly's Weight-Loss Empire Keeps Expanding As Mounjaro, Zepbound Generate Nearly $15 Billion

Eli Lilly and Co. (NYSE:LLY) stock traded higher Wednesday after the drugmaker reported second-quarter results that topped Wall Street expectations and raised its full-year revenue outlook, driven by continued demand for its diabetes and obesity treatments.

Benzinga

Patients Paid Less for GLP-1s While Total Spending Climbed, and Formularies Have Been Swinging Ever Since

A study found GLP-1 out-of-pocket costs fell as total spending rose. Here is what formulary swings mean for your coverage at renewal.

Medical Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

AbbVie vs Eli Lilly: 1 Is Clearly the Better Dividend Stock to Buy and Hold for the Next 10 Years

While one continues reinvesting for growth, the other has rewarded shareholders for 54 years in a row.

Barchart

Medicare's New $50 GLP-1 Weight-Loss Program Just Launched: Find Out if You Qualify

Medicare's GLP-1 Bridge launched July 1, 2026. Up to 3.8M seniors may qualify for $50/month Wegovy, Zepbound, or Foundayo. Here's the eligibility breakdown.

Medical Daily

The $50 GLP-1 Bridge: How to Get Affordable Weight-Loss Meds Starting July 1

Beginning July 1, qualifying Medicare recipients will be able to take weight-loss drugs for $50 per month through the new Medicare GLP-1 Bridge program. However,...

Saving Advice

Eli Lilly’s Employer Push Could Unlock New GLP-1 Demand

Eli Lilly is launching Employer Connect to expand Zepbound access while its oral GLP-1 orforglipron just topped Novo Nordisk's Rybelsus in a head-to-head trial.

MarketBeat

Read news from The Economist, FT, and more,
with one subscription

Drugmaker Eli Lilly announces new plant in Pennsylvania as part of broader domestic expansion

Drugmaker Eli Lilly and Co. says it'll build a $3.5 billion manufacturing facility in Pennsylvania, as the company expands domestic production and capitalizes on surging sales of obesity and diabetes treatments

The Independent UK

Ozempic, Mounjaro, Wegovy, or Zepbound? This ETF Holds Them All

As weight loss drugs move from injections to pills, this thematic ETF provides broad exposure for investors looking to profit from the industry’s next leg up.

MarketBeat

As Eli Lilly Cuts Zepbound Prices, Should You Buy, Sell, or Hold LLY Stock?

Eli Lilly has decided to slash prices of its weight loss drug Zepbound, making it more accessible to customers.

Barchart

Novo Nordisk's Stock Slump Shows The GLP‑1 Trade's Side Effect: ETF Concentration Risk

Novo Nordisk’s (NYSE:NVO) nearly 11% pre-market drop on Monday and subsequent 9% dip at market open, in the aftermath of disappointing topline results from its evoke/evoke+ Alzheimer’s trials, is more than a pipeline setback. It’s a stress test for healthcare ETFs that have quietly become GLP-1 momentum vehicles. With two…

Benzinga

Skip the Waiting Room: Your 2025 Guide to Getting Zepbound Online Safely

The year 2025 marks a new era in digital healthcare in Canada, where patients no longer need to wait weeks for appointments or stand in long lines at pharmacies to receive vital medications.

inkl

New Walmart Partnership to Let Patients Buy Eli Lilly's Zepbound Without Insurance Hassles

Eli Lilly partners with Walmart to sell its weight-loss drug Zepbound nationwide, giving patients easier, insurance-free access through LillyDirect.

International Business Times

Daily weight loss pill achieves main goal in late-stage trial

Data from an earlier study of the drug in patients without diabetes sent company shares tumbling

The Independent UK

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

2 Outstanding ‘Strong Buy’ Stocks to Grab in August

These two stocks offer a rare combination of income and growth.

Benzinga

Wegovy, Zepbound Prices Drop, But Most Patients Still Can't Afford Long-Term Use: 'Coverage Is Not The Same As Access,' Says Expert

MarketBeat

Hims’ Weight Loss Expansion: Real Growth or Just Hype?

Will Hims and Hers' addition of Eli Lilly's Zepbound to its weight loss platform be a big new growth driver? Or, is this development all bark and no bite?

MarketBeat

Is Viking Therapeutics the Next Blockbuster GLP-1 Stock?

Viking Therapeutic may have a GLP-1 blockbuster on their hands with VK2735 as it produces weight loss at 5X the speed of Novo Nordisk's Wegovy GLP-1 drug.

Get all your
news in one place.

100's of premium titles.
One news app.

MarketBeat

Eli Lilly: 4 Reasons Investors Shouldn’t Miss This Opportunity

Eli Lilly shares are down 17.7% from its highs. The company posted 128% YoY revenue jump in its Mounjaro GLP-1/GIP treatment with no signs of slowing down.

Kiplinger

The Future of Weight-Loss Drugs for Investors

Weight-loss drugs’ impact could reach far beyond their target user, potentially creating headwinds for shares of snack makers and packaged-food firms, as well as medical device makers that specialize in knee replacements, insulin pumps and sleep apnea machines.

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.